5 Things Gilead Sciences' Management Just Said That You'll Want to Know
Last week, Gilead Sciences (NASDAQ: GILD) generated plenty of buzz with the announcement of its planned acquisition of Kite Pharma (NASDAQ: KITE). On Wednesday, several of the company's top executives sat down at the Citi biotech conference to field questions.
Gilead Sciences COO Kevin Young, chief scientific officer Norbert Bischofberger, and CFO Robin Washington participated in what was billed as a "fireside chat." Here are five questions that Gilead's management answered that you'll want to know about.
Image source: Getty Images.
Source: Fool.com
GSK plc ADR Stock
€36.80
1.110%
With 6 Buy predictions and not the single Sell prediction the community is currently very high on GSK plc ADR.
With a target price of 49 € there is a positive potential of 33.15% for GSK plc ADR compared to the current price of 36.8 €.
